FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2754-2755 June 28, 2007 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

To the Editor: Although islet transplantation is an option for patients with type 1 diabetes, even those who become insulin-independent after engraftment have islet-graft function that is estimated to be less than 30% of that in a healthy person.¹ In fact, most patients resume insulin treatment within 2 years after transplantation.²

Islet-cell transplantation is accomplished by embolizing the islets by means of the portal vein into the liver.³ Because available tools to study transplanted islets have been limited, the liver has been considered a "black box" in clinical islet transplantation. Here we demonstrate the use of scanning with positron-emission tomography . . . [Full Text of this Article]

This article has been cited by other articles:

• Vantyghem, M.-C., Kerr-Conte, J., Arnalsteen, L., Sergent, G., Defrance, F., Gmyr, V., Declerck, N., Raverdy, V., Vandewalle, B., Pigny, P., Noel, C., Pattou, F. (2009). Primary Graft Function, Metabolic Control, and Graft Survival After Islet Transplantation. Diabetes Care 32: 1473-1478 [Abstract] [Full Text]  
• Rickels, M. R., Mueller, R., Markmann, J. F., Naji, A. (2009). Effect of Glucagon-Like Peptide-1 on {beta}- and {alpha}-Cell Function in Isolated Islet and Whole Pancreas Transplant Recipients. J. Clin. Endocrinol. Metab. 94: 181-189 [Abstract] [Full Text]